Suppr超能文献

[使用左旋聚乳酸进行面部年轻化:约298例连续病例]

[Facial rejuvenation using L-polylactic acid: about 298 successive cases].

作者信息

Olivier Masveyraud F

机构信息

Chirurgie plastique, 14, avenue Kleber, 75116 Paris, France.

出版信息

Ann Chir Plast Esthet. 2011 Apr;56(2):120-7. doi: 10.1016/j.anplas.2010.09.011. Epub 2010 Oct 20.

Abstract

AIM OF THE STUDY

Patients seeking care of facial ageing demand an aesthetic result that appears natural and is very safe, with techniques the less invasive possible. Our series of cases helps analyse the efficiency and safety of L-polylactic acid in the management of facial ageing.

PATIENTS AND METHOD

Retrospective analysis of a single series of patients treated with L-polylactic acid (Sculptra™) between September 2000 and September 2007. All patients over 18 years, consulting for facial ageing and/or loss of volume and treated with L-polylactic acid injections, were included in our evaluation. Patients with facial lipoatrophy related to HIV were excluded from this evaluation.

RESULTS

The series consist of 298 patients who received a total of 582 injections of L-polylactic acid. The reason for consultation was basically facial ageing (85.9%) and loss of facial volume (12.1%). Ninety-one percent patients were satisfied with the correcting effect. Fourteen patients (4.7%) showed a late adverse event: palpable but non-visible subcutaneous indurations (11 patients, 3.7%) and deep, little visible, multiple granuloma-like nodules that required treatment (three patients, 1%).

CONCLUSION

L-polylactic acid is a filler that facilitates natural correction of ageing with minimum adverse event. Its mechanism of action gives it a special place among other injectable materials. The surgeon who conducts adipocyte grafting will appreciate its ease of use and remodelling volumising effect.

摘要

研究目的

寻求面部抗衰治疗的患者期望获得自然且非常安全的美学效果,所采用的技术应尽可能微创。我们的系列病例有助于分析左旋聚乳酸在面部抗衰治疗中的有效性和安全性。

患者与方法

对2000年9月至2007年9月间接受左旋聚乳酸(塑然雅™)治疗的单一系列患者进行回顾性分析。所有18岁以上因面部衰老和/或容量缺失前来咨询并接受左旋聚乳酸注射治疗的患者均纳入我们的评估。与HIV相关的面部脂肪萎缩患者被排除在本评估之外。

结果

该系列包括298例患者,共接受了582次左旋聚乳酸注射。咨询的原因主要是面部衰老(85.9%)和面部容量缺失(12.1%)。91%的患者对矫正效果满意。14例患者(4.7%)出现晚期不良事件:可触及但不可见的皮下硬结(11例患者,3.7%)以及需要治疗的深部、几乎不可见的多个肉芽肿样结节(3例患者,1%)。

结论

左旋聚乳酸是一种能以最小不良事件促进自然抗衰矫正的填充剂。其作用机制使其在其他可注射材料中占有特殊地位。进行脂肪细胞移植的外科医生会欣赏其易用性和重塑容积的效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验